{
    "organizations": [],
    "uuid": "5c5a4846e0d960ed021c831862bbb331a9193210",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bioverativ-announces-first-patient/brief-bioverativ-announces-first-patient-dosed-in-phase-3-study-of-bivv009-for-cold-agglutinin-disease-treatment-idUSFWN1QO0D6",
    "ord_in_thread": 0,
    "title": "BRIEF-Bioverativ Announces First Patient Dosed In Phase 3 Study Of BIVV009 For Cold Agglutinin Disease Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Bioverativ Inc:\n* BIOVERATIV ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 STUDY OF BIVV009 FOR TREATMENT OF COLD AGGLUTININ DISEASE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T20:38:00.000+02:00",
    "crawled": "2018-03-06T14:50:12.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "bioverativ",
        "inc",
        "bioverativ",
        "announces",
        "first",
        "patient",
        "dosed",
        "phase",
        "study",
        "bivv009",
        "treatment",
        "cold",
        "agglutinin",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}